MaxCyte, Inc. (MXCT): Total Liabilities
$31.02M
As of 2025-12-31
$25.92M
As of 2026-06-30
-1.7%
3-year compound annual growth
+10.8%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $31.02M | -6.6% | 2026-03-25, Balance as of period end |
| 2024-12-31 | $33.22M | -8.0% | 2026-03-25, Balance as of period end |
| 2023-12-31 | $36.11M | +10.5% | 2025-03-11, Balance as of period end |
| 2022-12-31 | $32.69M | +54.0% | 2024-03-12, Balance as of period end |
| 2021-12-31 | $21.22M | +14.4% | 2023-03-15, Balance as of period end |
| 2020-12-31 | $18.55M | n/a | 2022-03-22, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| MaxCyte, Inc. (MXCT) | 2025-12-31 | $31.02M | -6.6% |
| OmniAb, Inc. (OABI) | 2025-12-31 | $33.89M | -10.7% |
| Foxo Technologies Inc. (FOXO) | 2025-12-31 | $33.50M | -8.1% |
| NRC Health (NRC) | 2025-12-31 | $120.89M | +19.4% |
| bioAffinity Technologies, Inc. (BIAF) | 2025-12-31 | $3.68M | -5.8% |
| Absci Corp (ABSI) | 2025-12-31 | $26.85M | -22.1% |
| iSpecimen Inc. (ISPC) | 2025-12-31 | $6.44M | +6.7% |
| OneMedNet Corp (ONMD) | 2025-12-31 | $5.12M | -74.0% |
| Medpace Holdings, Inc. (MEDP) | 2025-12-31 | $1.52B | +18.9% |
Compare MXCT, OABI, FOXO, NRC side by side · Screen every company in Services-Commercial Physical & Biological Research ↗